Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Tucatinib in Healthy Japanese and Caucasian Subjects
NCT03914755Phase 1Completed
- Sponsor
- Seagen Inc.
- Start
- May 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tucatinib in HER2-positive breast cancer (3 cohorts), sponsored by Seagen Inc. Primary endpoints: Maximum observed concentration at 14 days, Time of maximum observed concentration at 14 days and 3 more. Started May 2019; status: completed.
02
Drugs
tucatinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT03914755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03914755.